Rinvoq Receives FDA Approval for Crohn's Disease

Rinvoq, a JAK inhibitor available as a daily pill, has been approved by the FDA in the US and the European Medicines Agency for treatment of moderate to severe Crohn's disease. It was approved in Great Britain a couple of months ago.

It had previously been approved for treating mod to severe UC, rheumatoid arthritis, psoriatic arthritis, etc.

It is approved as a second line medication for those who fail anti-TNFs such as Remicade or Humira.

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-moderately-severely-active-crohns-disease

https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq

https://www.fiercepharma.com/pharma/abbvies-rinvoq-scores-its-7th-fda-nod-one-crohns-disease

https://finance.yahoo.com/news/u-fda-approves-rinvoq-upadacitinib-162500452.html

Post Edited (beave) : 5/19/2023 8:59:23 PM (GMT-8)

Since the cost is ten times less than Remicade or Humira it will likely become a first line drug for crohn's and colitis. Studies so far have shown its as effective as Remicade or Humira.